I recently attended The Association of Clinical Data Management Conference, where I gave the final keynote. Alongside my talk I was privileged to hear some insights into the Anti-Doping programme at the London Olympics, hence the title of this post. Having heard the intrusive urine collection process that athletes had to go through, I’m rather glad I was not an athlete!
Anyway, on to innovation and the pharmaceutical industry. Here’s the slide deck from the presentation below. I’m happy to take interested people through the slides via a Google Hangout. Simply get in touch if interested and I will be happy to run a collaborative online masterclass.
The main points we explored at the conference may be summarised:
- The differences between creativity and innovation, which are poorly understood in my long experience.
- Strategies and techniques for creativity and innovation, drawn from our toolkit of 130 + approaches, based on 18 years of teaching these at MBA level and which recently beat well-branded innovation companies to a pitch. We’re writing a book on innovation and creativity presently.
- The impact of big data and a world where analysis must be married with creativity if innovation is to occur. Data is estimated to be rising by 40% compound interest rate to 45 ZB by 2020. This offers us the possibility of ‘drowning in data’ or ‘swimming with information’. In a world where everything is measureable and measured, the opportunity for doing things that seem intuitively cool is potentially diminished.
- The importance of Failure in the context of Success. All successful innovators have failed many times, yet we live in a world where the expectation is ‘right first time innovation’. This paradox must be resolved.
Read more about all of this in “The Music of Business“. Check the references out below:
And finally, let’s see where the title of this blog emanated from: